# Generate Biomedicines Inc. (GENB)

Source: https://www.quantisnow.com/company/GENB
Generated: 2026-11-18T05:24:01.664Z

- Ticker: GENB
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2026
- SEC CIK: 0002100782

## Latest GENB news and filings

- 2026-11-12 12:20 UTC [Earnings] [Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/generate-biomedicines-reports-third-quarter-2026-financial-results-and-provides-6786180)
- 2026-11-12 12:16 UTC [SEC Form 8-K] [Generate Biomedicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/generate-biomedicines-inc-filed-sec-form-8-k-results-of-operations-6786171)
- 2026-11-12 12:06 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Generate Biomedicines Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-generate-biomedicines-inc-6786123)
- 2026-11-05 18:16 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by Generate Biomedicines Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-generate-biomedicines-inc-6775506)
- 2026-11-04 21:05 UTC [SEC Form 4] [Director Arnold Frances sold $184,733 worth of shares (11,409 units at $16.19) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 220,063 units (SEC Form 4)](https://www.quantisnow.com/insight/director-arnold-frances-sold-184733-worth-of-shares-11409-units-6772401)
- 2026-10-30 01:10 UTC [2027 Could Finally Be the Year Cancer Is on the Ropes!](https://www.quantisnow.com/insight/2027-could-finally-be-the-year-cancer-is-on-the-6764235)
- 2026-10-29 20:12 UTC [SEC Form 144] [SEC Form 144 filed by Generate Biomedicines Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-generate-biomedicines-inc-6763660)
- 2026-10-22 11:00 UTC [Conference Announcement] [Generate Biomedicines to Participate in November Investor Conferences](https://www.quantisnow.com/insight/generate-biomedicines-to-participate-in-november-investor-conferences-6754290)
- 2026-10-14 13:45 UTC [AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test](https://www.quantisnow.com/insight/ai-designed-biologics-are-moving-from-the-screen-to-the-bench-6746228)
- 2026-10-13 20:30 UTC [Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases](https://www.quantisnow.com/insight/generate-biomedicines-and-zealand-pharma-enter-collaboration-and-license-agreement-6745199)
- 2026-10-13 20:30 UTC [Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases](https://www.quantisnow.com/insight/zealand-pharma-and-generate-biomedicines-enter-collaboration-and-license-agreement-6745196)
- 2026-10-01 11:00 UTC [Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer](https://www.quantisnow.com/insight/roswell-park-generate-biomedicines-launch-exclusive-clinical-trial-of-armored-6731316)
- 2026-09-08 11:09 UTC [Conference Announcement] [Generate Biomedicines Inc. to Participate in September Investor Conferences](https://www.quantisnow.com/insight/generate-biomedicines-inc-to-participate-in-september-investor-conferences-6707412)
- 2026-09-03 20:05 UTC [SEC Form 4] [Director Arnold Frances sold $16,002 worth of shares (1,000 units at $16.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.43% to 231,472 units (SEC Form 4)](https://www.quantisnow.com/insight/director-arnold-frances-sold-16002-worth-of-shares-1000-units-6705030)
- 2026-09-02 20:20 UTC [SEC Form 144] [SEC Form 144 filed by Generate Biomedicines Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-generate-biomedicines-inc-6703287)
- 2026-09-01 20:27 UTC [SEC Form 144] [SEC Form 144 filed by Generate Biomedicines Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-generate-biomedicines-inc-6701541)
- 2026-08-25 23:28 UTC [SEC Form 8-K] [Generate Biomedicines Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/generate-biomedicines-inc-filed-sec-form-8-k-regulation-fd-disclosure-6694834)
- 2026-08-06 11:00 UTC [Dividends] [Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/generate-biomedicines-inc-reports-second-quarter-2026-financial-results-and-6667038)
- 2026-08-06 10:00 UTC [SEC Form 8-K] [Generate Biomedicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/generate-biomedicines-inc-filed-sec-form-8-k-results-of-operations-6666854)
- 2026-08-06 10:01 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Generate Biomedicines Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-generate-biomedicines-inc-6666849)
- 2026-06-22 12:00 UTC [Public Offering] [AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts](https://www.quantisnow.com/insight/advancell-signs-128000-square-foot-full-building-lease-at-iqhqs-6610082)
- 2026-05-28 20:20 UTC [Conference Announcement] [Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference](https://www.quantisnow.com/insight/generate-biomedicines-inc-to-participate-in-goldman-sachs-47th-annual-6577328)
- 2026-05-15 20:00 UTC [SEC Form SCHEDULE 13G filed by Generate Biomedicines Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-generate-biomedicines-inc-6556954)
- 2026-05-15 12:33 UTC [SEC Form SCHEDULE 13G filed by Generate Biomedicines Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-generate-biomedicines-inc-6555984)
- 2026-05-07 10:16 UTC [Public Offering] [Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/generate-biomedicines-inc-reports-first-quarter-2026-financial-results-and-6537118)
- 2026-05-07 10:01 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Generate Biomedicines Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-generate-biomedicines-inc-6536962)
- 2026-05-07 10:00 UTC [SEC Form 8-K] [Generate Biomedicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/generate-biomedicines-inc-filed-sec-form-8-k-results-of-operations-6536947)
- 2026-04-13 12:52 UTC [Analyst Coverage Initiated] [H.C. Wainwright initiated coverage on Generate Biomedicines with a new price target](https://www.quantisnow.com/insight/hc-wainwright-initiated-coverage-on-generate-biomedicines-with-a-new-6497407)
- 2026-03-24 12:39 UTC [Analyst Coverage Initiated] [Piper Sandler initiated coverage on Generate Biomedicines with a new price target](https://www.quantisnow.com/insight/piper-sandler-initiated-coverage-on-generate-biomedicines-with-a-new-6466354)
- 2026-03-24 12:39 UTC [Analyst Coverage Initiated] [Morgan Stanley initiated coverage on Generate Biomedicines with a new price target](https://www.quantisnow.com/insight/morgan-stanley-initiated-coverage-on-generate-biomedicines-with-a-new-6466353)
- 2026-03-24 12:39 UTC [Analyst Coverage Initiated] [Cantor Fitzgerald initiated coverage on Generate Biomedicines](https://www.quantisnow.com/insight/cantor-fitzgerald-initiated-coverage-on-generate-biomedicines-6466352)
- 2026-03-24 12:39 UTC [Analyst Coverage Initiated] [Guggenheim initiated coverage on Generate Biomedicines with a new price target](https://www.quantisnow.com/insight/guggenheim-initiated-coverage-on-generate-biomedicines-with-a-new-price-6466351)
- 2026-03-24 12:38 UTC [Analyst Coverage Initiated] [Goldman initiated coverage on Generate Biomedicines with a new price target](https://www.quantisnow.com/insight/goldman-initiated-coverage-on-generate-biomedicines-with-a-new-price-6466350)
- 2026-03-12 21:00 UTC [SEC Form 3] [New insider Pioneering Medicines 02, Llc claimed ownership of 1,562,500 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-pioneering-medicines-02-llc-claimed-ownership-of-1562500-6445207)
- 2026-03-06 21:55 UTC [Insider Buy] [Chief Executive Officer Nally Michael bought $240,000 worth of shares (20,000 units at $12.00), increasing direct ownership by 4% to 572,707 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-nally-michael-bought-240000-worth-of-shares-6435364)
- 2026-03-02 23:09 UTC [SEC Form 4] [SEC Form 4 filed by Director Vessey Rupert](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-vessey-rupert-6423092)
- 2026-03-02 23:05 UTC [Insider Buy] [Chief People Officer Grous Beth bought $4,800 worth of shares (300 units at $16.00) (SEC Form 4)](https://www.quantisnow.com/insight/chief-people-officer-grous-beth-bought-4800-worth-of-shares-6423082)
- 2026-03-02 23:02 UTC [SEC Form 4] [SEC Form 4 filed by Director Arnold Frances](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-arnold-frances-6423075)
- 2026-03-02 22:58 UTC [SEC Form 4] [SEC Form 4 filed by Chief Legal Officer & GC Martin Sean](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-legal-officer-gc-martin-6423054)
- 2026-03-02 22:58 UTC [SEC Form 4] [SEC Form 4 filed by Chief Medical Officer Lee Laurie Anne](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-medical-officer-lee-laurie-6423053)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/GENB
- Earnings history: https://www.quantisnow.com/earnings/GENB
- Dividend history: https://www.quantisnow.com/dividends/GENB
- Insider transactions: https://www.quantisnow.com/insiders/GENB
- Options chain: https://www.quantisnow.com/options/GENB
- SEC 8-K filings only: https://www.quantisnow.com/company/GENB/8-k
- RSS and alerts for GENB: https://www.quantisnow.com/docs/rss-feeds.md
